Clinical Research

Government-funded program wants better AI for managing heart failure in the US
The long-term goal is to bring 24-7 cardiac care to every American, even those living in counties with no cardiologists.
Acoramidis bests tafamidis in head-to-head comparison of ATTR-CM drugs
Acoramidis was associated with a 43% lower risk of diuretic intensification and a 34% lower risk of clinical worsening overall.
TAVR timing: Waiting more than 6 months may hurt survival odds
When heart patients are diagnosed with severe AS, how quickly do they need to undergo TAVR? That was the focus of a new analysis published in Open Heart.
European Society of Cardiology joins effort to improve access to heart data
Accessing cardiology data for research or population health initiatives is still quite difficult in Europe. Could this new project help reverse that trend?
5 practice-changing trials from ESC Congress 2026
Damodhar Suresh, MD, spoke to Cardiovascular Business about some of the biggest studies presented during the annual ESC conference in Munich, Germany.

Ramon Varcoe explains the LIFE-BTK trial for the Abbott Esprit fully bioresobable scaffold at TCT23.

Fully bioresorbable stents boost care for CLI patients in LIFE-BTK trial

Ramon Varcoe, MBBS, co-principal investigator for the LIFE-BTK trial, discussed the results with Cardiovascular Business at TCT 2023. "I can't wait to start using these in my patients. It's going to make a huge difference."

Rasha Al-Lamee, MBBS, PhD, a cardiologist with the National Heart and Lung Institute in London

PCI benefits patients with stable chest pain, late-breaking data confirm

“Going forward, patients and medical teams have a choice of two pathways for chest pain relief: chest pain medication or PCI," one cardiologist said.

Firas Zahr, MD,director of interventional cardiology, co-director, complex heart valve program, Oregon Health and Science University, discusses the one-year outcomes for transferral transcatheter mitral valve replacement (TMVR) in the Medtronic Intrepid Early Feasibility Study presented at TCT 2023.

Intrepid transfemoral transcatheter mitral valve shows favorable results after 1 year

Firas Zahr, MD, spoke to Cardiovascular Business about early data on the Medtronic TMVR device. His team's study is designed to follow patients for a total of five years.

PHOTO GALLERY: Interventional cardiology technologies at TCT 2023

Browse through some of the many highlights from TCT 2023 in San Francisco.

Matthias Götberg discusses iFR vs. FFR from the National SWEDEHEART Quality Registry at #TCT2023. #iFR

iFR and FFR are equal, new long-term analysis confirms

There were some concerns among researchers after one study suggested iFR may increase the risk of mortality. New data presented at TCT 2023, however, showed that the two technologies are linked to similar outcomes.

Kendra Grubb discusses TAVR vs SAVR and the most recent data to explain choices with patients.

TAVR or SAVR? Where things stand now, from a surgeon's perspective

Kendra Grubb, MD, one of the country's leading experts on cardiac surgery, discussed what she tells her patients when they ask if TAVR is better than SAVR for treating severe aortic stenosis.

Samir Kapadia, MD, Cleveland Clinic, explains the WATCH TAVR study results that combined LAAO with transcatheter aortic valve replacement at TCT 2023. #TCT2023 #TAVR #Watchman #LAAO

TAVR and LAAO at the same time? Samir Kapadia breaks down the WATCH-TAVR trial

Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview.